Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\29784646
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Biochem+Soc+Trans
2018 ; 46
(3
): 659-668
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Latest developments in MUC1 immunotherapy
#MMPMID29784646
Taylor-Papadimitriou J
; Burchell JM
; Graham R
; Beatson R
Biochem Soc Trans
2018[Jun]; 46
(3
): 659-668
PMID29784646
show ga
Currently, there is renewed interest in attempting to recruit the host immune
system to eliminate cancers, and within this renewed activity, MUC1 continues to
arouse interest. MUC1 has been considered a possible therapeutic target for the
past 30 years as it is up-regulated, aberrantly glycosylated and its polarization
is lost in many adenocarcinomas. Moreover, MUC1 is expressed by some
haematopoietic cancers, including acute myeloid leukaemia and myeloma. Although
multiple clinical trials have been initiated and immune responses have been
documented, effective clinical benefit worthy of approval for general application
has not as yet been achieved. However, this does not appear to have quelled the
interest in MUC1 as a therapeutic target, as shown by the increase in the number
of MUC1-based clinical trials initiated in 2017 ( Figure 1). As with all
translational studies, incorporating new relevant research findings into
therapeutic strategy is difficult. Decisions are made to commit to a specific
strategy based on the information and data available when the trial is initiated.
However, the time required for preclinical studies and early trials can render
the founding concept not always appropriate for proceeding to a larger definitive
trial. Here, we summarize the attempts made, to date, to bring MUC1 into the
world of cancer immunotherapy and discuss how research findings regarding MUC1
structure and function together with expanded knowledge of its interactions with
the tumour environment and immune effector cells could lead to improved
therapeutic approaches.
ppbiost;46/3/659/BST20170400CF1F1BST-2017-0400CF1Figure 1.Number of MUC1-targeted
trials initiated each year.
|*Immunotherapy
[MESH]
|Antimetabolites, Antineoplastic/therapeutic use
[MESH]
|Clinical Trials as Topic
[MESH]
|Combined Modality Therapy
[MESH]
|Deoxycytidine/analogs & derivatives/therapeutic use
[MESH]
free
free
free
